Results 131 to 140 of about 19,378,005 (296)

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac   +16 more
wiley   +1 more source

Lyophilized lymph nodes for improved delivery of chimeric antigen receptor T cells [PDF]

open access: yes
Lymph nodes are crucial organs of the adaptive immune system, orchestrating T cell priming, activation and tolerance. T cell activity and function are highly regulated by lymph nodes, which have a unique structure harbouring distinct cells that work ...
Zhou, Ruyi   +21 more
core   +1 more source

Why CD4+ T cells matter in adoptive cell therapy for solid cancers

open access: yesImmuno-Oncology and Technology
Cytotoxic CD8+ T cells have been the focus of research efforts to improve the efficacy of anticancer adoptive cell therapies. However, emerging evidence is highlighting the critical role of CD4+ T cells in these treatments, including chimeric antigen ...
S. Jegatheeson   +4 more
doaj   +1 more source

Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib, a highly selective, non‐covalent Bruton tyrosine kinase inhibitor (BTKi) previously demonstrated durable efficacy and tolerable safety following covalent (c) BTKi therapy in heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Michael L. Wang   +36 more
wiley   +1 more source

Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity

open access: yes
: Hematological toxicity following Chimeric Antigen Receptor-T therapy in a patient with a prior allogeneic stem cell transplantation was resolved by the infusion of unselected donor-derived stem cell boost.
Sica, Simona   +8 more
core   +1 more source

Manufacturing chimeric antigen receptor T cells: issues and challenges [PDF]

open access: yes, 2019
Clinical trials of adoptively transferred CD19 chimeric antigen receptor (CAR) T cells have delivered unprecedented responses in patients with relapsed refractory B-cell malignancy.
Roddie, C   +4 more
core   +1 more source

Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities

open access: yes
The use of chimeric antigen receptor T (CAR-T) cells is a significant therapeutic improvement increasing the prognosis for patients with a variety of hematological malignancies.
Schroeder, Torsten   +7 more
core   +1 more source

Successful CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation in a secondary central nervous system lymphoma patient with COVID-19 infection: a case report and literature review

open access: yesFrontiers in Oncology
This paper reported a 64-year-old, secondary central nervous system lymphoma (sCNSL) patient with COVID-19 infection during CD19 chimeric antigen receptor T-cell (CAR-T) therapy following autologous stem cell transplantation (ASCT).
Xiaoning Wang   +5 more
doaj   +1 more source

Barriers to Chimeric Antigen Receptor T-Cell Therapy

open access: yesJAMA Oncology
This cohort study examines barriers to access of CAR T-cell therapy among patients with hematologic cancer referred for this treatment.
Valtis, Yannis K.   +26 more
openaire   +3 more sources

Effects of Dietary Mannan Oligosaccharides on Growth, Disease Resistance, and Gut Microbiota in Zebrafish

open access: yesAnimal Research and One Health, EarlyView.
Supplementation with mannan oligosaccharides (MOS) enhances growth, disease resistance, antioxidant capacity, and gut microbiota diversity while suppressing inflammation, apoptosis, and strengthening intestinal barrier integrity in zebrafish challenged with LPS or DSS.
Zhiyuan Lu   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy